These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 20332318)

  • 1. Outcome of photodynamic therapy using NPe6 for bronchogenic carcinomas in central airways >1.0 cm in diameter.
    Usuda J; Ichinose S; Ishizumi T; Hayashi H; Ohtani K; Maehara S; Ono S; Honda H; Kajiwara N; Uchida O; Tsutsui H; Ohira T; Kato H; Ikeda N
    Clin Cancer Res; 2010 Apr; 16(7):2198-204. PubMed ID: 20332318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy for lung cancers based on novel photodynamic diagnosis using talaporfin sodium (NPe6) and autofluorescence bronchoscopy.
    Usuda J; Tsutsui H; Honda H; Ichinose S; Ishizumi T; Hirata T; Inoue T; Ohtani K; Maehara S; Imai K; Tsunoda Y; Kubota M; Ikeda N; Furukawa K; Okunaka T; Kato H
    Lung Cancer; 2007 Dec; 58(3):317-23. PubMed ID: 17698240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New aspects of photodynamic therapy for central type early stage lung cancer.
    Ikeda N; Usuda J; Kato H; Ishizumi T; Ichinose S; Otani K; Honda H; Furukawa K; Okunaka T; Tsutsui H
    Lasers Surg Med; 2011 Sep; 43(7):749-54. PubMed ID: 22057502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study.
    Taber SW; Fingar VH; Coots CT; Wieman TJ
    Clin Cancer Res; 1998 Nov; 4(11):2741-6. PubMed ID: 9829737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of multiple primary lung cancer in patients with centrally located early cancer lesions.
    Usuda J; Ichinose S; Ishizumi T; Hayashi H; Ohtani K; Maehara S; Ono S; Kajiwara N; Uchida O; Tsutsui H; Ohira T; Kato H; Ikeda N
    J Thorac Oncol; 2010 Jan; 5(1):62-8. PubMed ID: 19952800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
    Chan AL; Juarez M; Allen R; Volz W; Albertson T
    Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):72-8. PubMed ID: 15752124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photodynamic therapy of lung cancer.
    Lam S
    Semin Oncol; 1994 Dec; 21(6 Suppl 15):15-9. PubMed ID: 7992102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular determinants of photodynamic therapy for lung cancers.
    Usuda J; Ichinose S; Ishizumi T; Ohtani K; Inoue T; Maehara S; Imai K; Shima K; Ohira T; Kato H; Ikeda N
    Lasers Surg Med; 2011 Sep; 43(7):591-9. PubMed ID: 22057486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of GADD-45alpha and VEGF induced tumor recurrence via upregulation of IL-2 after photodynamic therapy using NPe6.
    Ohtani K; Usuda J; Ichinose S; Ishizumi T; Hirata T; Inoue T; Maehara S; Imai K; Kubota M; Tsunoda Y; Yamada M; Tsutsui H; Yamada K; Kuroiwa Y; Furukawa K; Okunaka T; Kato H
    Int J Oncol; 2008 Feb; 32(2):397-403. PubMed ID: 18202762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locally recurrent central-type early stage lung cancer < 1.0 cm in diameter after complete remission by photodynamic therapy.
    Furukawa K; Kato H; Konaka C; Okunaka T; Usuda J; Ebihara Y
    Chest; 2005 Nov; 128(5):3269-75. PubMed ID: 16306036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic therapy with mono-L-aspartyl chlorin e6 can cause necrosis of squamous cell carcinoma of tongue: experimental study on an animal model of nude mouse.
    Kobayashi W; Liu Q; Nakagawa H; Sakaki H; Teh B; Matsumiya T; Yoshida H; Imaizumi T; Satoh K; Kimura H
    Oral Oncol; 2006 Jan; 42(1):46-50. PubMed ID: 16266818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basic and clinical research on photodynamic therapy at Tokyo Medical University Hospital.
    Kato H; Usuda J; Okunaka T; Furukawa K; Honda H; Sakaniwa N; Suga Y; Hirata T; Ohtani K; Inoue T; Maehara S; Kubota M; Yamada K; Tsuitsui H
    Lasers Surg Med; 2006 Jun; 38(5):371-5. PubMed ID: 16788919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized photodynamic therapy with systemic photosensitizer following debulking technique for nonmelanoma skin cancers.
    Souza CS; Neves AB; Felício LA; Ferreira J; Kurachi C; Bagnato VS
    Dermatol Surg; 2007 Feb; 33(2):194-8. PubMed ID: 17300605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endovascular photodynamic therapy using mono-L-aspartyl-chlorin e6 to inhibit Intimal hyperplasia in balloon-injured rabbit arteries.
    Nagae T; Aizawa K; Uchimura N; Tani D; Abe M; Fujishima K; Wilson SE; Ishimaru S
    Lasers Surg Med; 2001; 28(4):381-8. PubMed ID: 11344521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung.
    Kato H; Furukawa K; Sato M; Okunaka T; Kusunoki Y; Kawahara M; Fukuoka M; Miyazawa T; Yana T; Matsui K; Shiraishi T; Horinouchi H
    Lung Cancer; 2003 Oct; 42(1):103-11. PubMed ID: 14512194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer.
    Usuda J; Tsunoda Y; Ichinose S; Ishizumi T; Ohtani K; Maehara S; Ono S; Tsutsui H; Ohira T; Okunaka T; Furukawa K; Sugimoto Y; Kato H; Ikeda N
    Lung Cancer; 2010 Feb; 67(2):198-204. PubMed ID: 19477032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [History of photodynamic therapy--past, present and future].
    Kato H
    Gan To Kagaku Ryoho; 1996 Jan; 23(1):8-15. PubMed ID: 8546474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model.
    Gomer CJ; Ferrario A
    Cancer Res; 1990 Jul; 50(13):3985-90. PubMed ID: 2354446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model.
    Wong Kee Song LM; Wang KK; Zinsmeister AR
    Cancer; 1998 Jan; 82(2):421-7. PubMed ID: 9445202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tailor-made approach to photodynamic therapy in the treatment of cancer based on Bcl-2 photodamage.
    Usuda J; Hirata T; Ichinose S; Ishizumi T; Inoue T; Ohtani K; Maehara S; Yamada M; Tsutsui H; Okunaka T; Kato H; Ikeda N
    Int J Oncol; 2008 Oct; 33(4):689-96. PubMed ID: 18813781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.